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stenting, no significant difference was noted (MACE: 13 vs. 
16%, p = 0.40).  Conclusions: Among patients with SVG dis-
ease, treatment with DES resulted in a better long-term out-
come than treatment with BMS. In contrast, no DES benefit 
was found in similarly sized native vessels regarding MACE. 
 Copyright © 2008 S. Karger AG, Basel 
 Introduction 
 Interventional revascularization therapy after coro-
nary artery bypass graft (CABG) surgery needs to be per-
formed in 1–2% of patients per year within the first 5 
years after surgery and in 4% per year subsequently  [1] . 
While atherosclerotic changes leading to severe obstruc-
tion or occlusion are present in almost half of all saphe-
nous vein grafts (SVG) after 11 years, the degeneration of 
these grafts starts early after surgery  [1] . Until recently, 
the standard treatment of SVG atherosclerosis was to re-
peat CABG  [2] . However, angioplasty alone  [3–6] and an-
gioplasty with stenting  [7–11] have emerged as alternative 
treatment options in the last years. Thus, treatment of 
SVG disease currently accounts for about 10% of all per-
cutaneous coronary interventions (PCI)  [12] . Since em-
bolization of friable material was a main problem with 
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 Abstract 
 Objectives: To define long-term efficacy of different stent 
types in saphenous vein graft (SVG) interventions.  Methods: 
In BASKET (Basel Stent Cost Effectiveness Trial), major ad-
verse cardiac events (MACE), i.e. cardiac death, myocardial 
infarction and symptom-driven target vessel revasculariza-
tion (TVR) were assessed after 18 months comparing drug-
eluting stents (DES) versus bare metal stents (BMS), and SVG 
and large native vessels ( 6 3.0 mm).  Results: Large vessel in-
terventions were performed in 605 patients. Patients with 
SVG interventions (n = 47, 8%) were older and had more of-
ten hypertension, prior myocardial infarction, prior revascu-
larization and multivessel disease and less frequent ST-ele-
vation myocardial infarction than patients with large native 
vessel interventions (n = 558, 92%). Stent number and length 
were higher in SVG than in large native vessel interventions. 
Baseline characteristics were similar for DES and BMS. In SVG 
stenting, long-term outcome was better in DES- than in 
BMS-treated patients (MACE 21 vs. 62%, p = 0.007, mainly 
due to TVR 18 vs. 46%, p = 0.045), but for large native vessel 
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percutaneous techniques, distal embolic protection  [13, 
14] and mechanical thrombectomy of large luminal 
thrombi  [15, 16] were beneficial regarding short-term 
major adverse clinical events (MACE), but long-term out-
come after PCI of SVG lesions remains poor, primarily 
due to the high incidence of restenosis and atheroscle-
rotic disease progression  [17, 18] .
 In recent years, drug-eluting stents (DES) have shown 
a proven benefit in reducing intimal hyperplasia and in 
stent restenosis for selected lesions  [19–22] , but the safety 
and efficacy of DES in the treatment of SVG lesions re-
mains unclear. Although recently much concern has been 
raised regarding the occurrence of late stent thrombosis 
after DES implantation  [23] , DES in de novo lesions of 
large native vessels  6 3.0 mm were beneficial compared 
with bare metal stents (BMS) in reducing the rate of re-
stenoses  [20, 22] . However, the efficacy of DES in the 
treatment of SVG lesions has been tested in both non-
randomized  [24, 25] and randomized  [26, 27] studies. 
Specifically, the RRISC (Reduction of Restenosis in Sa-
phenous Vein Grafts with Cypher Sirolimus-Eluting 
Stents) study demonstrated conflicting results with DES 
reducing late loss after 6 months  [26] but exposing to a 
long-term hazard with increased all-cause mortality after 
3 years  [27] . In contrast, a previous exploratory analysis 
of BASKET (Basel Stent Kosten Effektivitäts Trial/Basel 
Stent Cost Effectiveness Trial)  [28] demonstrated that 
SVG lesions carried a high risk of recurrent clinical events 
which could be reduced by the use of DES, but specific 
results were lacking  [29] .
 In light of these results, we used the unselected, real-
world patient population of BASKET  [28] to define the 
long-term safety and efficacy of DES in SVG comparing 
the outcome of patients undergoing PCI of SVG lesions 
with that of patients undergoing PCI of similarly sized 
native vessels.
 Patients and Methods 
 Study Design 
 This is a secondary analysis of BASKET as pre-specified in the 
study protocol. The design of the study has been described previ-
ously  [28] . In brief, BASKET, a randomized, prospective study, 
evaluated the cost-effectiveness of two DES, i.e. the sirolimus-
eluting Cypher  stent (Cordis, Johnson & Johnson, Miami Lakes, 
Fla., USA) and the paclitaxel-eluting Taxus  stent (Boston Scien-
tific, Natick, Mass., USA), compared to a 3rd generation cobalt-
chromium BMS (Vision  stent; Guidant, Indianapolis, Ind., 
USA). Patients were randomized in a 2: 1 fashion to DES and BMS 
with a 1: 1 randomization between the two DES types, and were 
followed for 18 months. Over 1 year, all patients undergoing PCI 
at our institution were enrolled in the study; the only exclusion 
criteria were a vessel diameter  1 4 mm (since the largest DES di-
ameter size available at the time of the study was 3.5 mm), reste-
notic lesions and no consent. The study was approved by the local 
institutional review board and each patient gave written informed 
consent.
 In a previous analysis of the same dataset, both SVG and vessel 
size were identified as predictors of late outcome  [29] . The present 
study serves as an exploratory analysis of this finding investigat-
ing baseline and outcome differences between SVG and similarly 
sized native vessels treated with different stent types including all 
patients with a PCI using a stent  6 3 mm in diameter; however, it 
was allowed to post-dilate 3.5-mm stents up to 4.0 mm, if neces-
sary. Of note, all SVG interventions up to 4.0-mm vessels were 
part of this group. The primary endpoint of this analysis was clin-
ically driven and a composite of MACE, i.e. cardiac death, non-
fatal myocardial infarction (MI) and non-MI-related target vessel 
revascularization (TVR). MACE including cause of death were 
adjudicated by an independent critical events committee blinded 
to the stent type used. Non-fatal MI was defined as typical symp-
toms with an elevation in cardiac enzymes, i.e. troponin I, tropo-
nin T or creatine phosphokinase above the upper limit, or typical 
ST changes in the electrocardiogram at the time of symptoms 
 [30] . TVR was defined as a clinical event since control angiogra-
phy was not allowed without symptoms or signs of ischemia. TVR 
related to MI was counted among MI events, differing from TVR 
not related to MI. Follow-up angiography was allowed only if clin-
ically indicated to eliminate the possibility of angiography-driven 
TVR.
 PCI was performed according to standard techniques with the 
final decision on the appropriate strategy left to the physician in 
charge. The use of distal embolic protection devices was not re-
quired in this study. Patients received a loading dose of 250–500 
mg aspirin i.v. or p.o. and clopidogrel 300 mg p.o. prior to PCI; the 
use of glycoprotein IIb/IIIa inhibitors was left to the discretion of 
the physician in charge but was mainly given in patients with 
acute coronary syndromes or suboptimal angioplasty results. Af-
ter PCI, long-term statin therapy was prescribed in all patients, as 
well as a maintenance dual antiplatelet therapy with aspirin 100 
mg and clopidogrel 75 mg daily for 6 months, irrespective of the 
stent type used. Patients were advised to stop clopidogrel after 6 
months, but to continue aspirin.
 Follow-Up 
 After 6 and 18 months, patients presented at the outpatient 
clinic or were contacted by a questionnaire with specific ques-
tions regarding rehospitalizations, adverse events and drug ther-
apy. Additional data were collected from primary care physicians, 
referring cardiologists or relatives when necessary. For the whole 
study, follow-up was complete in 823 (99.6%) patients regarding 
survival and 813 (98.4%) patients regarding all events.
 Statistical Analysis 
 All analyses were performed by intention to treat, with the 
primary aim to compare patients with DES and BMS. Quantita-
tive variables are presented as means  8 SD or medians  8 inter-
quartile ranges, as appropriate. Categorical variables are de-
scribed by their distribution. Two-group comparisons were done 
using the   2 test or Fisher’s exact test for categorical variables, 
where appropriate, and unpaired t test for quantitative variables. 
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Kaplan-Meier curves were used for calculating time-dependent 
occurrence of events, and the log-rank test to compare the differ-
ent groups. All p values were two-sided and considered statisti-
cally significant if p  ! 0.05. All calculations were performed with 
the use of a commercially available statistical package (SPSS 13.0, 
SPSS, Chicago, Ill., USA).
 Results 
 Patient Population 
 Between May 2003 and May 2004, 988 patients un-
derwent PCI, of whom 162 (16%) had to be excluded due 
to a target vessel diameter  6 4 mm (n = 23), restenotic 
lesions (n = 49) or no consent (n = 90). Of note, most pa-
tients excluded due to a vessel diameter  1 4 mm in fact 
had SVG disease; they could not be randomized because 
DES of this size were not available at the time of the 
study. In total, 826 patients were enrolled into BASKET, 
of whom 545 (66%) received DES (Cypher, n = 264, and 
Taxus, n = 281), and 281 (34%) BMS. Interventions in 
large vessels  6 3 mm were performed in 605 (73%) pa-
tients (SVG interventions in 47, 8%, and large native ves-
sel interventions in 558, 92%). Of the patients undergo-
ing PCI in SVG lesions, 34 (72%) were treated with DES 
(Cypher, n = 22, and Taxus, n = 12), and 13 (28%) with 
BMS ( fig. 1 ).
 Patient Characteristics 
 Patients undergoing SVG interventions were older and 
had more often hypertension, prior MI and prior PCI 
compared with patients with large native vessel lesions 
( table 1 ). In contrast, SVG patients were less frequently 
current smokers. Indication for PCI in SVG disease was 
less often acute ST-elevation MI and more often chronic 
angina compared with large native vessel disease. On av-
erage, patients with SVG lesions received more stents 
with a longer total length and a larger size than patients 
with large native vessel lesions.
 Except for a somewhat longer stent length in DES-
treated patients in large native vessel disease, baseline 
clinical and angiographic characteristics were similar 
among DES- and BMS-treated patients within the two 
groups ( table 1 ).
BMS
(n = 13)
DES
(n = 34)
BMS
(n = 200)
DES
(n = 358)
Screened patients with PCI
(n = 988)
BASKET
(n = 826)
Large vessels 3 mm
(n = 605)
<
Saphenous
vein grafts
(n = 47)
Large native
vessels
(n = 558)
Excluded (n = 162)
Vessel size
(n = 23)
<
4 mm
Restenosis
(n = 49)
No consent
(n = 90)
Small vessels
<3 mm
(n = 221)
 Fig. 1. Patient-flow chart of the study pop-
ulation.  
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 Outcome with DES versus BMS in SVG Lesions 
Compared with Large Native Vessel Lesions 
 After 18 months, the incidence of MACE in patients 
with SVG disease was 62% in the BMS group compared 
with 21% in the DES group (p = 0.007,  fig. 2 a). This dif-
ference was mainly driven by a higher non-MI related 
TVR rate in BMS- versus DES-treated patients (46 vs. 
18%; p = 0.045), while MI and cardiac death rates were 
not different. In contrast, the 18-month outcome in large 
native vessel disease was similar with both stent types 
Table 1. Baseline clinical and angiographic characteristics
All
(n = 605)
Bypass grafts Large native vessels pa
all
(n = 47)
BMS
(n = 13)
DES
(n = 34)
pb all
(n = 558)
BMS
(n = 200)
DES
(n = 358)
pb
Age, years 63811 7188 7188 7188 0.70 63811 63811 62811 0.61 <0.0001
Females, % 22 15 0 21 0.076 22 20 23 0.38 0.25
Prior MI, % 25 55 46 59 0.44 23 24 22 0.55 <0.0001
Prior PCI, % 16 43 39 44 0.73 14 14 14 0.99 <0.0001
Prior CABG, % 13 100 – – – 6 7 5 0.42 <0.0001
Diabetes, % 18 26 17 29 0.39 17 17 18 0.72 0.14
Hypertension, % 65 87 83 88 0.67 63 64 63 0.83 0.001
Hypercholesterolemia, % 76 83 92 79 0.28 75 78 74 0.31 0.26
Current smoking, % 31 13 0 18 0.12 33 33 33 0.92 0.005
Multivessel disease, % 65 100 – – – 62 63 62 0.91 <0.0001
Indication for PCI, % 0.11 0.85 0.03
STEMI 24 11 15 9 25 15 9
Acute coronary syndrome 36 34 54 27 36 54 27
Chronic angina 40 55 31 65 39 31 65
GP IIb/IIIa inhibitors, % 28 28 46 21 0.08 28 26 29 0.44 0.97
Warfarin, % 7 5 0 7 0.37 7 6 7 0.61 0.60
Implanted stents, n 1.781.0 2.281.3 2.481.5 2.181.2 0.48 1.780.9 1.681.0 1.780.9 0.61 <0.0001
≥1 stents, % 30 49 62 44 0.29 28 26 29 0.44 0.002
DES, % 65 72 – – – 64 – – – 0.34
Stent length, mm 31818 42826 46830 41825 0.59 30817 28816 31817 0.05 <0.0001
Stents ≥3.5 mm, % 35 49 17 29 0.39 34 33 34 0.71 0.033
STEMI = ST elevation; GP = glycoprotein.
 a Bypass grafts vs. large native vessels, t test, Fisher’s test, or 2 test, where appropriate.
 b BMS vs. DES, t test, Fisher’s test, or 2 test, where appropriate.
0
10
20
30
40
50
60
70
%
a
62
21
p = 0.007
TVR
46
18
p = 0.045
MI
0
6
p = 1.00
Cardiac
death
15
3
p = 0.18
BMS
DES
MACE
0
10
20
30
40
50
60
70
%
MACE
13
16
p = 0.40
TVR
11 11
p = 0.88
MI
3
7
p = 0.047
Cardiac
death
2 3
p = 0.43
BMS
DES
b
 Fig. 2. Cumulative clinical outcome after 
18 months in SVG ( a ) and large native ves-
sels ( b ) for BMS vs. DES (Fisher’s exact test 
or   2 test where appropriate).  
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used without any difference in cardiac death or non-MI-
related TVR rates ( fig. 2 b). Of note, the numerically high-
er MACE rates were mostly due to higher rates of non-
fatal MI in DES- versus BMS-treated patients during fol-
low-up (p = 0.047).
 As depicted in  figure 3 , outcome between the four 
groups was statistically different (p  ! 0.0001). This differ-
ence was mainly due to a much higher event rate in SVG 
lesions treated with BMS, whereas DES in SVG lesions 
and both stent types in large native vessel lesions had a 
similar efficacy in preventing MACE.
 Discussion 
 The present results demonstrate a high recurrence rate 
of clinical events after PCI of SVG lesions. While the high 
event rate of SVG lesions treated with BMS was reduced 
to the event rate of large native vessel interventions by the 
use of DES, no such effect was seen in patients with le-
sions of native vessels of similar size.
 In SVG, atherosclerosis with large, soft, friable plaques 
may develop early after CABG surgery due to surgical 
trauma, loss of intrinsic vascular supply and abrupt in-
crease in wall stress  [12, 17] . Morphologic features of ath-
erosclerotic SVG disease include concentric and diffuse 
changes, inflammatory infiltrates and absence of a fi-
brous cap  [18] . This special pathophysiology may respond 
more favorably to antiproliferative and immunosuppres-
sive effects of drugs used in DES. Therefore, the benefi-
cial clinical effect of both paclitaxel and sirolimus in SVG 
lesions as shown in the present study might be due to 
their effect on concentric intimal hyperplasia and local 
inflammation.
 Similar to previous studies  [31, 32] , the present analy-
sis did not show any benefit of DES on outcome in large 
native vessel lesions. However, non-fatal MI rate was 
somewhat elevated in DES-treated patients with native 
large vessel interventions which might reflect an elevated 
rate of acute thrombotic stent occlusions, but this differ-
ence was small.
 Data on the effect of DES in PCI of SVG lesions are 
conflicting. A previously published retrospective analy-
sis showed a lower incidence of MACE in DES-treated 
patients after 6 months  [24] . In another retrospective 
 cohort study, the incidence of death, MI and TVR was 
lower in DES compared with BMS patients after a mean 
follow-up time of 9 months after SVG PCI  [25] . Newer 
retrospective data show no significant difference in long-
term outcome over a mean of 33 months with DES com-
pared with BMS  [33] . However, the recently published 
randomized RRISC study in patients undergoing SVG 
PCI showed a higher mortality rate for DES after 3 years 
of follow-up (29 vs. 0%; p  ! 0.001)  [27] , although late loss 
was reduced by the use of a sirolimus-eluting DES after
6 months  [26] . The significance of this result is unclear, 
since mid-term angiographic results and long-term clin-
ical results were highly conflicting in this study. Con-
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 Fig. 3. Kaplan-Meier curves with log-rank 
test for survival without major adverse 
cardiac events in patients undergoing PCI 
on bypass grafts versus large native vessels 
using different types of stents.  
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trary to RRISC and in accordance to previous retrospec-
tive studies, our data support the notion that compared 
with BMS DES exert a long-term beneficial clinical effect 
on SVG interventions. However, large randomized trials 
with long-term follow-up are warranted to define the ef-
ficacy and safety of DES in SVG interventions.
 Limitations 
 Since this is a predefined but retrospective secondary 
analysis of prospectively collected data, this study is in 
contrast to the prospective, randomized RRISC study. 
Therefore, the current analysis is subject to inherent lim-
itations. This analysis was neither specifically random-
ized nor stratified for SVG disease, which may explain 
small imbalances between stent groups. Furthermore, 
the small sample size, specifically the small number of 
patients with BMS, and the follow-up duration of 18 
months may preclude final conclusions. In addition, pa-
tients with a vessel diameter  6 4 mm were not included 
in this analysis due to the non-availability of adequately 
sized DES at the time of the study, which may have pro-
duced a selected SVG population with a smaller vessel 
size than expected. Since the exact TVR localization was 
not specified in this analysis, no conclusion can be drawn 
regarding the differentiation between in-stent restenoses 
and additional lesions. However, because stent length was 
not statistically different between DES and BMS in SVG 
lesions, rates of additional lesions causing events might 
be similar in both groups. Finally, the study was not pow-
ered to detect differences between the two DES used, but 
there was no difference in event rates between the two 
stents in the 18-month follow-up of the overall BASKET 
study  [23] . These findings and limitations hold true for 
first-generation DES only, but data for newer DES are still 
lacking.
 Conclusions 
 Patients with SVG lesions undergoing PCI have a 
worse outcome than patients with native vessel lesions of 
the same size. Among patients with SVG lesions, treat-
ment with DES results in a reduced rate of MACE after 
18 months, specifically TVR, compared with treatment 
with BMS, but no DES benefit was found in interventions 
in similarly sized native vessels regarding MACE. There-
fore, these findings suggest that patients with SVG lesions 
undergoing PCI might best be treated with DES.
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